Hepatology

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, November 8, 2023

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023

Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.

Key Points: 
  • Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.
  • Operating expenses in the third quarter of 2023 were $73.7 million, compared to $40.2 million in the third quarter of 2022.
  • Adjusted EBITDA was $49.1 million in the third quarter of 2023, compared to $68.8 million in the third quarter of 2022.
  • – Ironwood generated approximately $32.5 million in cash from operations in the third quarter of 2023, compared to $69.1 million in cash from operations in the third quarter of 2022.

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Thursday, November 9, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.
  • Title: Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy
    Company-Hosted Webcast and Conference Call Information:
    Precision will host a conference call and webcast on Monday, November 13, 2023 at 4:30 PM ET to discuss PBGENE-HBV program updates.
  • The dial-in conference call number is (800) 715-9871 and the conference ID number for the call is 3866428.
  • Participants may access the live webcast, and accompanying presentation materials, as well as the archived webcast on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations .

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, November 8, 2023

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Key Points: 
  • BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
  • As a result of the transaction, Intercept has become a wholly owned subsidiary of Alfasigma, and the common stock of Intercept has ceased to be traded on the NASDAQ Stock Market.
  • Stefano Golinelli, Chairman of Alfasigma, commented: “At Alfasigma, the passion we have for Pharmaceuticals is in our DNA - and a driver for our ambitious international growth plans.
  • Francesco Balestrieri, CEO of Alfasigma, added: “Today, we complete a transformational acquisition which strongly aligns with our strategy of building a solid presence in gastroenterology and hepatology, Alfasigma’s core business areas.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, November 8, 2023

Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Key Points: 
  • Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
  • As a result of the transaction, Intercept has become a wholly owned subsidiary of Alfasigma, and the common stock of Intercept has ceased to be traded on the NASDAQ Stock Market.
  • Stefano Golinelli, Chairman of Alfasigma, commented: “At Alfasigma, the passion we have for Pharmaceuticals is in our DNA - and a driver for our ambitious international growth plans.
  • Thus, we are delighted to announce the successful outcome of our tender offer for Intercept Pharmaceuticals, Inc.

Minimally Invasive Needle-Based Biopsy Instruments Drive Growth in the Biopsy Devices Market, Offering Precision and Patient Comfort - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023

The biopsy devices market has significantly impacted the healthcare industry through several key developments:

Key Points: 
  • The biopsy devices market has significantly impacted the healthcare industry through several key developments:
    Shift to Minimally Invasive Biopsies: The market has witnessed a notable shift from conventional surgical biopsies to minimally invasive needle-based biopsy instruments.
  • Improved Accuracy and Precision: Biopsy devices have evolved to offer increased accuracy and precision, enabling earlier and more accurate disease diagnosis, particularly in cases of cancer.
  • Enhanced Patient Outcomes: By improving the accuracy, precision, and accessibility of biopsy procedures, these devices have contributed to better patient outcomes across various medical conditions.
  • The global biopsy devices market is segmented as follows:
    Tissue Biopsy (Tissue Biopsy Devices, Consumables)

Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting

Retrieved on: 
Wednesday, November 8, 2023

DUBLIN, Nov. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the presentation of 11 scientific abstracts with findings from the latest clinical and health economics research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 during the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting, taking place November 10-14, 2023 in Boston, MA.

Key Points: 
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9111651-mallinckrodt-aasld-2023-...
    Please see Limitation of Use and Important Safety Information, including Boxed Warning, below.
  • Data collected in retrospective, pooled, database, or post hoc analyses may have errors or omissions.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economic outcomes may not be solely attributable to TERLIVAZ.
  • TERLIVAZ® is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Boston Pharmaceuticals To Present New Phase 2a Data From Investigational BOS-580 NASH Program at AASLD The Liver Meeting® 2023

Retrieved on: 
Tuesday, November 7, 2023

Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • BOS-580 is a long-acting, highly engineered fibroblast growth factor 21 (FGF21) analog administered via a once-monthly subcutaneous injection.
  • BOS-580 is designed to reduce liver fat content, liver inflammation as evidenced by biomarkers of liver injury and fibrosis and improve metabolism as evidenced by the impact on metabolic biomarkers in patients with NASH.
  • We are especially pleased that our presentation on the impact of BOS-580 treatment in subgroups of NASH patients who also have diabetes was designated as a poster of distinction by AASLD, placing it among the foremost presentations at this year’s meeting,” stated Sophie Kornowski, PharmD, CEO of Boston Pharmaceuticals.

Gilead Sciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
  • During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
  • During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock.
  • Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.